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randomized between dose-escalation of the entire primary tumour or 
to the high FDG uptake region inside the primary tumour. Plans are 
normalized to the same mean lung dose, while giving 66 Gy in 24 
fractions to involved lymph nodes. The trial has already accrued 66 
patients and will soon be extended to five participating centres. The 
head and neck trial investigates the impact of delivering a high 
radiation dose to the most active part of the tumour, as seen on the 
PET-CT scan by adaptive radiotherapy. Patients are randomized 
between a conventional IMRT and adaptive IMRT by redistribution of 
the radiation dose: with higher doses given to the most active part of 
the tumour and low doses at the border of the CTV. In the adaptive 
arm, the treatment plan is modified to account for anatomical 
changes occurring over the course of therapy. In a factorial design, 
patients are randomized between 1) conventional and adaptive 
radiotherapy and 2) radiotherapy plus cisplatin or cetuximab. The 
sensitivity for cisplatin and cetuximab is estimated by both molecular 
profiling research and the 3D measurement of 89- Zirconium uptake in 
the tumour. The first patient just completed the treatment with the 
combination of radiotherapy and cetuximab in the head and neck 
cancer study. Although this is a very sophisticated and intensive 
approach, the treatment has proceeded without problems. 
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There is growing concern about the possible long-term risks to 
radiotherapy patients from neutrons, which are generated as a by-
product either in high-energy photon beams, or proton beams.  The 
usual approach to estimating the risk from neutrons is to use ICRP risk 
factors and radiation weighting factors for neutrons.  There are a 
number of problems with this, and indeed the ICRP state clearly that 
their numbers are approximations, which should only be used for 
radiation protection guidelines, and not for individuals.  According to 
the ICRP scheme, the risk from neutrons is determined by means of 
the relative biological effectiveness (RBE) of neutrons compared to 
photons for which the risks are better known.  However there is 
considerable uncertainty about how RBE for neutrons varies with dose 
and neutron energy, or whether the RBE model is even appropriate.  
Two major reasons for this are that it is very difficult to obtain risk 
data in exposure situations where the neutron energy is confined to a 
narrow spectrum (or even well known), and the occurrence of risk 
events at the low doses of interest is very low giving poor statistics.  
Previous research on risks from neutron risk has mainly been single-
discipline.  That is, the results have been dependent on a single 
experimental or epidemiological approach.  By contrast, the ANDANTE 
project uses three different disciplines in parallel.  This is analogous 
to taking images of an object using three different imaging modalities 
and combining them to produce an image much sharper than any of 
the individual images.  The three parallel approaches are: 
Physics: a track structure model is used to contrast the patterns of 
damage to cellular macro-molecules from neutrons compared to 
photons.  The simulations reproduce the same energy spectra as are 
used in the other two approaches. 
Stem cell radiobiology: stem cells from thyroid, salivary gland, and 
breast tissue are given well characterised exposures to neutrons and 
photons.  A number of endpoints are used to estimate the relative risk 
of damage from neutrons compared to photons.  As well, irradiated 
cells will be transplanted into mice to investigate the incidence of 
progression into tumours.   
Epidemiology: the relative incidence rates of second cancers of the 
thyroid, salivary gland, and breast following paediatric radiotherapy 
(conventional radiotherapy for photons and proton therapy for 
neutrons) are investigated in a pilot single-institution study, leading to 
a multi-institution prospective study. 
The project has completed the first of its four years.  Progress on 
characterising the exposure beams, isolation and initial exposures of 
stem cells, and data collection for the epidemiological studies will be 
presented.  
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Out-of field neutron exposure of proton therapy might lead to 
enhanced formation of second cancer. The goal of the Andante 
project is to estimate the risk of second cancer from out-of field 
neutron exposure and compare this with other treatment modalities. 
This study focuses on two specific cancers that may be detected as 
second malignant neoplasms following pediatric radiotherapy:salivary 
gland and thyroid gland cancer. It has been suggested that adult stem 
cells are a critical target for radiation carcinogenesis. Therefore, in 
this study adult stem cells from murine salivary and thyroid glands 
were isolated and expanded in culture. Stem cell containing spheroids 
(multicellular 3D structures) could be obtained from both murine 
salivary and thyroid glands in non-adherent cultivation of cell 
suspensions of salivary and thyroid gland tissue in serum-free 
conditions. After digestion of spheroids into single cells, cells were 
exposed to different doses (0.1, 0.5, 1, 2, 5 Gy) of ϒ-irradiation. To 
determine transformation, in vitro self-renewal and differentiation 
capacity were investigated of irradiated cells and were compared to 
unirradiated cells. In addition, salivary and thyroid cells were isolated 
from inducible p53 knockout mice to test the carcinogenesis potential 
of the model. Transplantation of irradiated stem cells in photon-
irradiated salivary glands will be performed to get information on 
carcinogenic transformation in vivo. In the future, stem cells will be 
exposed to neutrons and will be compared to the exposure of photons.  
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Purpose/Objective: Intensity-modulated radiotherapy (IMRT) 
credentialing for the 22074-24071 Head and Neck (H&N) EORTC study 
was performed using the anthropomorphic head phantom from the 
Radiological Physics Center (RPC; RPCph). Institutions were also 
retrospectively requested to irradiate their own in-house phantom 
(Instph) using the same treatment plan in the framework of a Virtual 
Phantom Project (VPP) for IMRT credentialing. Both measurement and 
calculations for the RPCph and Instph were sent to the EORTC for 
central analysis using the digital quality assurance (QA) platform. 
Materials and Methods: Calculated and measured 2D dose matrices on 
the Instph were requested from centers and send to a dedicated 
secured EORTC uploader. RPC analyzed the credentialing 
measurements performed in the RPCph using the VPP metrics. Data 
from the RPCph and INSTph were thereafter centrally analyzed and 
inter-compared by the QA team using commercially available 
software. 
Results: Eighteen institutions participated to the VPP. The 
measurements of 6 (33%) institutions could not be analyzed centrally, 
as a result of incomplete datasets (n=4) or dose-matrix format issues 
(n=2). All other centers (n=12; 66%) could be credentialed successfully 
using the VPP protocol and the dose-gradient produced by the IMRT 
plans were acceptable in all cases using the RPC criteria. The same 
number of institutions (n=12) was successfully credentialed using the 
more stringent 5%/5 mm pass at the 90% pixel cutoff-level gamma 
analysis criteria. A passing rate of 84.8±13.1%, 97.8±3.2% and 
99.3±1.2% for the 3%/3 mm,5%/5 mm and 7%/4mm QA criteria, 
respectively, was observed with RPCph. A corresponding passing rate of 
93.5±5.4%, 98.9±1.5% and 99.4±1.2% for 3%/3 mm, 5%/5 mm and 
7%/4mm QA criteria , respectively, was observed with the VPP using 
Instph data. 
Conclusions: IMRT credentialing for H&N prospective trials using 
institutional phantom measurements is possible and was successful in 
all cases using the RPC passing criteria.  
   
PD-0226   
New robotic phantom: Evaluation of performance in radiotherapy 
H. Arenbeck1, C. Bornemann2, N. Escobar2, K. Bollue1, M. Eble2, D. 
Abel1 
1RWTH-Aachen University, Institute of Automatic Control, Aachen, 
Germany  
2University Hospital Aachen, Clinic for Radiooncology and 
Radiotherapy, Aachen, Germany  
 
